| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/AAC.01694-17 |
| P8608 | Fatcat ID | release_bhdwbgssirctnl5rhiiw6h7qjm |
| P932 | PMC publication ID | 5700310 |
| P698 | PubMed publication ID | 29038260 |
| P2093 | author name string | Michael N Dudley | |
| Dongxu Sun | |||
| Olga Lomovskaya | |||
| Debora Rubio-Aparicio | |||
| Kirk Nelson | |||
| P2860 | cites work | Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections | Q40392497 |
| Complete nucleotide sequence of KPC-3-encoding plasmid pKpQIL in the epidemic Klebsiella pneumoniae sequence type 258. | Q42421230 | ||
| Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae | Q42638031 | ||
| Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3. | Q45199771 | ||
| Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae | Q45565740 | ||
| Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae. | Q53735018 | ||
| SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing | Q24629733 | ||
| Carbapenemase-producing Klebsiella pneumoniae: molecular and genetic decoding | Q27013922 | ||
| Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases | Q27698519 | ||
| Prokka: rapid prokaryotic genome annotation | Q29616643 | ||
| Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae | Q33474709 | ||
| Nationwide Surveillance of Clinical Carbapenem-resistant Enterobacteriaceae (CRE) Strains in China | Q33715837 | ||
| Carbapenem resistance in Enterobacteriaceae: here is the storm! | Q34266306 | ||
| The antibiotic resistance crisis: part 1: causes and threats | Q34471028 | ||
| Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects | Q34537388 | ||
| Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence | Q34737663 | ||
| Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia. | Q35076943 | ||
| Tigecycline susceptibility and the role of efflux pumps in tigecycline resistance in KPC-producing Klebsiella pneumoniae. | Q35570710 | ||
| Klebsiella pneumoniae ST258 producing KPC-3 identified in italy carries novel plasmids and OmpK36/OmpK35 porin variants | Q35867410 | ||
| In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase | Q35960745 | ||
| Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae | Q35960957 | ||
| Regulation of transcription of the repA1 gene in the replication control region of IncFII plasmid NR1 by gene dosage of the repA2 transcription repressor protein | Q36290313 | ||
| Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects | Q36290773 | ||
| Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions | Q36361921 | ||
| Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam | Q36644679 | ||
| Structure, Function and Regulation of Outer Membrane Proteins Involved in Drug Transport in Enterobactericeae: the OmpF/C - TolC Case | Q36743082 | ||
| Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae | Q37203731 | ||
| Pharmacokinetic and pharmacodynamic properties of meropenem | Q37247125 | ||
| Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. | Q37263324 | ||
| Multi-institute analysis of carbapenem resistance reveals remarkable diversity, unexplained mechanisms, and limited clonal outbreaks | Q37626179 | ||
| Functional characterization of Tn4401, a Tn3-based transposon involved in blaKPC gene mobilization | Q38726335 | ||
| Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study | Q39170725 | ||
| High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae | Q40282001 | ||
| Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City | Q40284963 | ||
| Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States | Q40342728 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Klebsiella pneumoniae | Q132592 |
| P577 | publication date | 2017-10-16 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae | |
| P478 | volume | 61 |
| Q92452234 | Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018 |
| Q92441701 | Antibiotic resistance breakers: current approaches and future directions |
| Q92690711 | Avibactam Sensitizes Carbapenem-Resistant NDM-1-Producing Klebsiella pneumoniae to Innate Immune Clearance |
| Q91825577 | Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms |
| Q96136650 | How to manage KPC infections |
| Q90712005 | Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Klebsiella pneumoniae Bacteremia and Abscess in a Liver Transplant Recipient |
| Q88417556 | Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae |
| Q52564980 | Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria. |
| Q89864907 | Meropenem/Vaborbactam versus Ceftazidime/Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections |
| Q58733616 | Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections |
| Q58746821 | Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant |
| Q57036779 | Pathogen-Specific Clinical Trials: A New Paradigm in Clinical Trials for Multidrug-Resistant Organisms |
| Q89517185 | Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam |
| Q90007513 | Recognizing and Overcoming Resistance to New Beta-Lactam/Beta-Lactamase Inhibitor Combinations |
| Q64911007 | The "Old" and the "New" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. |
| Q89997000 | The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections |
| Q64108242 | Treatment of Infections Due to MDR Gram-Negative Bacteria |
Search more.